2seventy bio Inc. (NASDAQ:TSVT) finished Wednesday with an addition of $0.03 to close at $5.82, an upside of 0.52 percent. An average of 1,141,960 shares of common stock have been traded in the last five days. There was a fall of -$0.63 in the past week, and it reached a new high 1 time over the past 12 months. The last 20 days have seen an average of 1,154,545 shares traded, while the 50-day average volume stands at 898,456.
TSVT stock has decreased by -46.21% in the last month. The company shares reached their 1-month lowest point of $5.64 on 08/09/23. With the stock rallying to its 52-week high on 02/06/23, shares of the company touched a low of $5.73 and a high of $18.88 in 52 weeks. It has reached a new high 16 times so far this year and lost -37.89% or -$3.55 in price. In spite of this, the price is down -69.17% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
TSVT stock investors should be aware that 2seventy bio Inc. (TSVT) stock had its last reported insider trading activity 7 days ago on Aug 03. In this transaction, the insider spent $55,499. Chief Financial Officer, Baird William D III, disposed of 6,906 shares at a price of $6.13 on Aug 03. The insider now owns more than $42,304 worth of shares. Prior to that, Chief Scientific Officer Gregory Philip D went on to Sale 3,966 shares at $6.13 each on Aug 03. An amount of $24,295 was transacted.
Valuation Metrics
2seventy bio Inc. (TSVT) stock’s beta is 1.30. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 2.37, the price-to-book (PB) ratio at 0.63.
Financial Health
The quick ratio of 2seventy bio Inc. for the three months ended March 30 was 5.10, and the current ratio was 5.10, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the quarter ending March 30. 2seventy bio Inc.’s EBITDA margin for the year ending March 30 is -274.74%. Its gross profit as reported stood at $74.92 million compared to revenue of $91.5 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, 2seventy bio Inc.’s return on assets was -29.80%.
Earnings Surprise
In the quarter under review, the net income was down than the previous quarter. The company posted a net income of -$47.02 million in the quarter, while revenues of -$23.14 million were shrunk -82.28%. The analyst consensus anticipated 2seventy bio Inc.’s latest quarter earnings to come in at -$1.22 per share, but it turned out to be -$1.08, a 11.50% surprise. For the quarter, EBITDA amounted to -$49.46 million. Shareholders own equity worth $50.2 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at 2seventy bio Inc. (TSVT) price momentum. RSI 9-day as of the close on 09 August was 7.48%, suggesting the stock is oversold, with historical volatility in this time frame at 35.00%.
As of today, TSVT’s price is $5.98 -9.77% or -$0.63 from its 5-day moving average. TSVT is currently trading -46.99% lower than its 20-day SMA and -40.73% lower than its 100-day SMA. However, the stock’s current price level is -51.42% below the SMA50 and -58.22% below the SMA200.
The stochastic %K and %D were 3.28% and 2.74%, respectively, and the average true range (ATR) was 0.51. With the 14-day stochastic at 3.38% and the average true range at 0.53, the RSI (14) stands at 13.18%. The stock has reached -0.63 on the 9-day MACD Oscillator while the 14-day reading was at -1.72.
Analyst Ratings
Morgan Stanley downgraded 2seventy bio Inc. (NASDAQ: TSVT) to a an Equal-weight rating in its most recent analyst report. Previously, the stock was rated as an Overweight. The consensus rating for 2seventy bio Inc. (TSVT) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell TSVT, while 1 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 6 others rate it as a “buy”.
What is TSVT’s price target for the next 12 months?
Analysts predict a range of price targets between $13.00 and $33.00, with a median target of $27.00. Taking a look at these predictions, the average price target given by analysts for 2seventy bio Inc. (TSVT) stock is $25.00.
